Page last updated: 2024-10-19
phenylacetic acid and Acute Hepatic Failure
phenylacetic acid has been researched along with Acute Hepatic Failure in 1 studies
phenylacetic acid : A monocarboxylic acid that is toluene in which one of the hydrogens of the methyl group has been replaced by a carboxy group.
Research Excerpts
| Excerpt | Relevance | Reference |
|---|
| "L-Ornithine and phenylacetate act synergistically to successfully attenuate increases in arterial ammonia, which is accompanied by a significant decrease in extracellular brain ammonia and prevention of intracranial hypertension in pigs with ALF." | 7.75 | L-ornithine phenylacetate attenuates increased arterial and extracellular brain ammonia and prevents intracranial hypertension in pigs with acute liver failure. ( Cobos, MJ; Fuskevåg, OM; Jalan, R; Kalstad, T; Kristiansen, RG; Maehre, H; Revhaug, A; Rose, CF; Ytrebø, LM, 2009) |
| "L-Ornithine and phenylacetate act synergistically to successfully attenuate increases in arterial ammonia, which is accompanied by a significant decrease in extracellular brain ammonia and prevention of intracranial hypertension in pigs with ALF." | 3.75 | L-ornithine phenylacetate attenuates increased arterial and extracellular brain ammonia and prevents intracranial hypertension in pigs with acute liver failure. ( Cobos, MJ; Fuskevåg, OM; Jalan, R; Kalstad, T; Kristiansen, RG; Maehre, H; Revhaug, A; Rose, CF; Ytrebø, LM, 2009) |
Research
Studies (1)
| Timeframe | Studies, this research(%) | All Research% |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|
| Ytrebø, LM | 1 |
| Kristiansen, RG | 1 |
| Maehre, H | 1 |
| Fuskevåg, OM | 1 |
| Kalstad, T | 1 |
| Revhaug, A | 1 |
| Cobos, MJ | 1 |
| Jalan, R | 1 |
| Rose, CF | 1 |
Clinical Trials (1)
Trial Overview
| Trial | Phase | Enrollment | Study Type | Start Date | Status |
|---|
| A Phase 2a Study to Evaluate the Safety and Tolerability of OCR-002 (Ornithine Phenylacetate) in the Treatment of Patients With Acute Liver Failure/Severe Acute Liver Injury[NCT01548690] | Phase 2 | 47 participants (Actual) | Interventional | 2012-06-30 | Completed |
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Trial Outcomes
Change in Ammonia
To evaluate the effect of OCR-002 on ammonia levels in patients with acute liver failure/severe acute liver injury (NCT01548690)
Timeframe: Baseline and 72 Hours
| Intervention | Percent Change (Mean) |
|---|
| Maximum Dose Level 3.33 g/24h | 41.2 |
| Maximum Dose Level 6.65 g/24h | 16.6 |
| Maximum Dose Level 10 g/24h | 41.8 |
| Maximum Dose Level 20g/24h | 38.4 |
Measurement of OCR-002 Plasma Concentration
To evaluate the steady state pharmacokinetic and pharmacodynamic profile of OCR-002 in patients with impaired and intact renal function using urinary phenylacetylglutamine (PAGN) as a surrogate marker (NCT01548690)
Timeframe: 24 Hours after last infusion
| Intervention | micrograms per millileter (Mean) |
|---|
| Maximum Dose Level 3.33 g/24h | 65.6 |
| Maximum Dose Level 6.65 g/24h | 32.2 |
| Maximum Dose Level 10 g/24h | 33.4 |
| Maximum Dose Level 20g/24h | 104.9 |
Neurological Function Measured by the Orientation Log (O-log)
The orientation log focuses on orientation to place, time, and circumstance. There are 10 items on the orientation log, which are scored 0-3. A spontaneous correct response is awarded 3 points. A spontaneous response that is lacking or incorrect, but a correct response is provided following a logical cue is awarded 2 points. A score of 1 is given if spontaneous and cued responses are lacking or incorrect, but a correct response is provided in a recognition format. A score of 0 is given if the spontaneous, cued, or recognition format does not generate a correct answer. Scores from the 10 items are summed and the final score ranges from 0 to 30. (NCT01548690)
Timeframe: 30 Days
| Intervention | units on a scale (Mean) |
|---|
| Maximum Dose Level 3.33 g/24h | 23.8 |
| Maximum Dose Level 6.65 g/24h | 24.0 |
| Maximum Dose Level 10 g/24h | 24.0 |
| Maximum Dose Level 20g/24h | 24.0 |
Neurological Function Measured by the West Haven Criteria (WHC) for Hepatic Encephalopathy
The West Haven Criteria (WHC) for Hepatic Encephalopathy measures the severity of encephalopathy and patient's level of consciousness. The scale ranges from 0 to 4; a minimum score of 0 represents a better outcome, and a maximum total score of 4 represents a worse outcome. A score of 0 corresponds to normal consciousness and behavior and normal neurological examination. A score of 1 corresponds to mild lack of awareness, shortened attention span, and impaired addition or subtraction; mild asterixis or tremor. A score of 2 corresponds to lethargy, disorientated or inappropriate behavior, obvious asterixis; slurred speech. A score of 3 corresponds to somnolent but arousable, gross disorientation or bizarre behavior, muscle rigidity and clonus; hyperreflexia. A score of 4 corresponds to coma and decerebrate posturing. (NCT01548690)
Timeframe: 120 hours from start of infusion
| Intervention | units on a scale (Mean) |
|---|
| Maximum Dose Level 3.33 g/24h | 2.4 |
| Maximum Dose Level 6.65 g/24h | 3.2 |
| Maximum Dose Level 10 g/24h | 1.6 |
| Maximum Dose Level 20g/24h | 1.8 |
Number of Participants That do Not Tolerate the Administered Dose and Had Grade 3 or 4 Treatment Emergent Adverse Events as a Measure of Safety and Tolerability
To evaluate the safety and tolerability of OCR-002 in patients with acute liver failure/severe acute liver injury (NCT01548690)
Timeframe: 30 Days
| Intervention | Participants (Count of Participants) |
|---|
| Maximum Dose Level 3.33 g/24h | 0 |
| Maximum Dose Level 6.65 g/24h | 0 |
| Maximum Dose Level 10 g/24h | 0 |
| Maximum Dose Level 20g/24h | 0 |
Other Studies
1 other study available for phenylacetic acid and Acute Hepatic Failure